MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Cardium Therapeutics, Inc. (CXM) Pursuit For Growth Anchored By Key Elements, Strategic Design 0 comments
    Oct 18, 2013 6:02 PM | about stocks: CXM

    As an asset-based health sciences and regenerative medicine company, Cardium Therapeutics focuses on acquiring and developing innovative products and businesses that have the potential to fulfill significant unmet medical needs.

    In its quest to develop a portfolio of medical product candidates for eventual commercialization, Cardium's strategy is to build on its core products and candidates and focus on five specific elements:

    •Advance its ASPIRE Generx® clinical study for patients with advanced coronary artery disease at major medical centers in Russia

    •Establish development and commercialization partnerships for Generx® in newly industrializing countries such as India, China, and Brazil

    •Secure commercialization partners for its FDA-cleared Excellagen® advanced wound care product

    •Expand the To Go Brands® healthy nutraceutical supplement brand platform

    •Seek out high-potential acquisition and license opportunities

    With its existing lineup of brands and products, the company has established a firm presence in the cardiovascular, wound care management, and nutraceutical markets. The design of the Cardium's business model creates multiple opportunities for growth while mitigating risk by eliminating the company's reliance on any single technology platform or product type.

    Currently, the company's lead commercial product is Excellagen, which received U.S. FDA clearance for marketing and sale in the United States. Cardium plans to advance the product's market reach in the U.S. and internationally, as well as seeks to develop new extensions and applications of the products. The company is working to obtain marketing and sale approval of the product in South Korea as well as through the CE Mark application process in the European Union.

    For more information, visit cardiumthx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CXM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.